Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism

Androgen receptor (AR) activation is the primary driving factor in prostate cancer which is initially responsive to castration but then becomes resistant (castration-resistant prostate cancer (CRPC)). CRPC cells still retain the functioning AR which can be targeted by other therapies. A recent promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Tim A. D., Phyu, Su M., Alzyoud, Kholoud S., Tseng, Chih-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498927/
https://www.ncbi.nlm.nih.gov/pubmed/28717648
http://dx.doi.org/10.1155/2017/4793465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498927/
https://www.ncbi.nlm.nih.gov/pubmed/28717648
http://dx.doi.org/10.1155/2017/4793465

Ejemplares similares